2.4.0.8000170 - Disclosure - Note 12- Subsequent Eventstruefalsefalse1false falsefalseD130101_130630http://www.sec.gov/CIK0001455694duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_DisclosureTextBlockAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes2false 2us-gaap_SubsequentEventsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00NOTE 12 SUBSEQUENT EVENTS   In accordance with ASC 855-10 Company management reviewed all material events through the date of this report and there is one material subsequent event to report.   On July 2, 2013, the Company entered into a material transfer agreement with The University of Texas Medical Branch (UTMB) for consideration.   On July 17, 2013, the Company filed an Amended and Restated Certificate of Designation, Preferences and Rights of Series A Convertible Preferred Stock (the Designation).  The Designation provides for:  (A) the elimination of anti-dilution price protection for future issuance below the conversion price; (B) an increase in the trigger price at which the Company can convert the Series A Preferred Stock into Common Stock from 200% of the conversion price to 300%; (C) removal of the Companys election to pay dividends in cash; and (D) an increase in the number of authorized shares of Series A Preferred Stock from 5,000 to 10,000, each with a stated value of $1,000 per share.  falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.No definition available.false0Note 12- Subsequent EventsfalseNote 12- Subsequent EventsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://signpathpharma.com/20130630/role/idr_DisclosureNote12SubsequentEvents12